Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats
Open Access
- 1 June 2011
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 300 (6), H2316-H2322
- https://doi.org/10.1152/ajpheart.01259.2010
Abstract
The induction of renal cyclooxygenase-2 (COX-2) in diabetes has been implicated in the renal functional and structural changes in models where hypertension or uninephrectomy was superimposed. We examined the protective effects of 3 mo treatment of streptozotocin-diabetic rats with a highly selective COX-2 inhibitor (SC-58236) in terms of albuminuria, renal hypertrophy, and the excretion of TNF-α and TGF-β, which have also been implicated in the detrimental renal effects of diabetes. SC-58236 treatment (3 mg·kg−1·day−1) of diabetic rats resulted in reduced urinary excretion of PGE2, 6-ketoPGF1α, and thromboxane B2, all of which were increased in the diabetic rat compared with age-matched nondiabetic rats. However, serum thromboxane B2 levels were unchanged, confirming the selectivity of SC-58236 for COX-2. The renal protective effects of treatment of diabetic rats with the COX-2 inhibitor were reflected by a marked reduction in albuminuria, a reduction in kidney weight-to-body weight ratio, and TGF-β excretion and a marked decrease in the urinary excretion of TNF-α. The protective effects of SC-58236 were independent of changes in plasma glucose levels or serum advanced glycation end-product levels, which were not different from those of untreated diabetic rats. In an additional study, the inhibition of COX-2 with SC-58236 for 4 wk in diabetic rats resulted in creatinine clearance rates not different from those of control rats. These results confirm that the inhibition of COX-2 in the streptozotocin-diabetic rat confers renal protection and suggest that the induction of COX-2 precedes the increases in cytokines, TNF-α, and TGF-β.Keywords
This publication has 31 references indexed in Scilit:
- Treatment of diabetic rats with a peroxynitrite decomposition catalyst prevents induction of renal COX-2American Journal of Physiology-Heart and Circulatory Physiology, 2011
- Chronic COX Inhibition Reduces Diabetes-Induced Hyperfiltration, Proteinuria, and Renal Pathological Markers in 36-Week B6-Ins2Akita MiceAmerican Journal of Nephrology, 2009
- Fenofibrate Treatment of Diabetic Rats Reduces Nitrosative Stress, Renal Cyclooxygenase-2 Expression, and Enhanced Renal Prostaglandin ReleaseThe Journal of pharmacology and experimental therapeutics, 2007
- Evidence for a Role of Transforming Growth Factor (TGF)-β1 in the Induction of Postglomerular Albuminuria in Diabetic NephropathyDiabetes, 2007
- CYCLO‐OXYGENASE‐2 INHIBITION ATTENUATES THE PROGRESSION OF NEPHROPATHY IN UNINEPHRECTOMIZED DIABETIC RATSClinical and Experimental Pharmacology and Physiology, 2006
- Effect of Tempol on Renal Cyclooxygenase Expression and Activity in Experimental Diabetes in the RatThe Journal of pharmacology and experimental therapeutics, 2005
- Role of COX-2 in the Enhanced Vasoconstrictor Effect of Arachidonic Acid in the Diabetic Rat KidneyHypertension, 2003
- Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppressionThe FASEB Journal, 2002
- Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction.JCI Insight, 1994
- Pathological changes in streptozotocin induced diabetes mellitus in the ratExperimental pathology, 1986